Chief Commercial Officer
Sven Ericksson lead the licensing and commercialization efforts of the company’s lead candidate arfolitixorin (Modufolin®). Prior to joining Isofol, Mr. Erickson served as Director of Medical Affairs in the Nordic region at PTC Therapeutics. Preceding his employment at PTC Therapeutics was his role as Product Search and Evaluation Manager at Medivir, a research-based pharmaceutical company with focus on oncology, managing in-licensing operations. Before joining Medivir in 2014, Mr. Erickson have also held different positions at Novartis including Scandinavian Medical Head of Critical Care. Mr. Eriksson has a PhD in Experimental Oncology from The Karolinska Institute, Sweden.
Sven joined Isofol in 2017.
Position: Chief Commercial Officer
Holdings*: 16 332 shares, 176 300 warrants**